Tonix Enrolls First Patient in MDD Phase 2 Trial of TNX-102 SL

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a significant milestone in its fight against major depressive disorder (MDD): the first patient has been enrolled in the HORIZON Phase 2 trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with MDD. This randomized, double-blind, placebo-controlled study is expected to enroll approximately 360 patients at about 30 U.S. sites. The trial will assess changes in depression severity after six weeks of treatment, along with measures of sleep quality, anxiety, and global clinical improvement. TNX-102 SL is designed to improve sleep quality, which the company believes plays an important role in MDD, and is already FDA-approved under the brand name TONMYA(TM) for fibromyalgia in adults. Tonix has previously shown signals for improving depressive symptoms and subjective sleep quality in earlier clinical studies, and the therapy is also being developed for post-traumatic stress disorder, Long COVID, alcohol use disorder, and agitation in Alzheimer’s disease.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

This news matters because MDD affects millions of people worldwide, and current treatments often have significant side effects or limited efficacy. Tonix’s approach, targeting sleep quality as a core component of depression, offers a novel therapeutic strategy. If successful, TNX-102 SL could provide a new, well-tolerated first-line monotherapy for MDD, addressing a critical unmet need. The company’s progress also underscores the potential of repurposing existing drugs for new indications, accelerating the path to patients. Investors and patients alike should watch this trial closely, as positive results could reshape the depression treatment landscape. For more details, visit https://nnw.fm/dORql.